Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache

Phase 2

Completed

• Conditions: Migraine With Aura; Migraine Without Aura

• Registration Number: NCT00123201
• Lead Sponsor: Solvay Pharmaceuticals

Brief Summary

The primary objective of this study is to evaluate the efficacy and safety of dronabinol MDI for the acute treatment of moderate to severe migraine headache.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2005-07-21
• Study First Submitted QC: 2005-07-21
• Study First Posted: 2005-07-22
• Study Start: 2005-09
• Status Verified: 2006-09
• Primary Completion: 2007-03
• Study Completion: 2007-03
• Last Update Submitted: 2015-01-15
• Last Update Posted: 2015-01-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Male or female subjects 18 to 65 years, inclusive, with clinically diagnosed migraine with or without aura based on International Headache Society criteria

Exclusion Criteria

• Subjects who experience migraine with prolonged aura; familiar hemiplegic migraine; migrainous infarction or basilar migraine; and those with greater than eight migraine attacks per month and/or greater than 14 migraine days per month.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (29)

Site 10; 🇺🇸 Huntsville, Alabama, United States

Site 8; 🇺🇸 Huntsville, Alabama, United States

Site 11; 🇺🇸 Tucson, Arizona, United States

Site 3; 🇺🇸 Anaheim, California, United States

Site 6; 🇺🇸 San Fransisco, California, United States

Site 15; 🇺🇸 Stockton, California, United States

Site 26; 🇺🇸 Melbourne, Florida, United States

Site 22; 🇺🇸 New Port Richey, Florida, United States

Site 18; 🇺🇸 Orange City, Florida, United States

Site 27; 🇺🇸 Pembroke Pines, Florida, United States

Scroll for more (19 remaining)